Subscribe to RSSSerious Step Backwards In Hospital Reporting MRSA
10 May 2010
WASHINGTON, May 10 — The Health Forum issued the following news release:
Responding to concerns about imposing a “severe burden” on hospitals, the Centers for Medicare & Medicaid Services May 7, 2010, notified hospitals that it has reversed course and no longer is requiring them to submit to the Buccaneer Data Systems Clinical Data Abstraction Center data that theypreviously reported to the Centers for Disease Control and Prevention on Methicillian-resistant Staphylococcus aureus.
MRSA is a bacterium responsible for several difficult-to-treat infections in patients. CMS’ Office of Clinical Standards and Quality withdrew its April 29 requirement for the data, which it said was intended to help estimate the accuracy of MRSA data reported to CDC and to assess the “accuracy of medical record-abstracted information at a hospital level, relative to national rates collected in other initiatives.”
In its May 7 letter, the agency said it is dropping the requirement to send the data, after listening to hospitals and “national and state association feedback about the severe burden to hospitals.” CMS said hospitals that submit the data voluntarily will be reimbursed for their costs.
“We sincerely apologize for any inconvenience that results from this request, and kindly request that your hospital continue to work collaboratively with your [Quality Improvement Organization] partner in improving MRSA rates and overall patient safety,” CMS said. “We appreciate CMS’ responsiveness to the concerns raised,” said Nancy Foster, AHA vice president for quality and patient safety. “We are glad that CMS’ decision will allow those participating in this project to stay focused on that very important goal.”
Medizone International, Inc. (Dually Traded: OTCBB/OTCQB: MZEI)
(http://medizoneint.com)
Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospitals, sports training facilities, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis.
Medizone International, Inc.
Post Office Box 742
Stinson Beach, CA 94970
Telephone: 415-868-0300
Fax: 415-868-2344
This release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.
Medizone International, Inc.
(OTCBB/OTCQB: MZEI)
Post Office Box 742
Stinson Beach, CA 94970
Telephone: 415-868-0300
Email: Operations@Medizoneint.com
Medizone International, Inc. is dually traded on the Over the Counter Bulletin Board and electronically on the OTCQB.
Link Here: Full Montage Stock Quote
Sign up for Email Notifications
Translator
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |